Study Conclusion:

Harmony Outcomes tested the safety and effectiveness of albiglutide, a glucagon-like peptide-1 receptor agonist in treating patients with Type 2 diabetes and cardiovascular disease. The study indicated the use of albiglutide produced a 22 percent reduction in the risk of major adverse cardiovascular events (MACE) when used in addition to standard of care.

 

Study Population:

Over 9,000 patients with Type 2 diabetes and cardiovascular disease at 610 sites in 28 countries.

 

Clinical Events Classification Insight:

Duke Clinical Research Institute provided clinical event classification, safety surveillance, and mega trial site management services for over 3,200 triggered events that included heart failure, stroke/ transient ischemic attack (TIA), revascularization, and death.